In a nutshell This study examined lenalidomide (Revlimid) as a consolidation strategy in patients with chronic lymphocytic leukemia (CLL) who have residual disease after treatment. This study reported good response improvements (in 45% of patients with residual disease). Lenalidomide may be particularly suited as a consolidation strategy after...
Read More
In a nutshell This study aimed to investigate the effect of therapeutic care for fatigue in breast cancer patients who are undergoing chemotherapy. This study concluded that therapeutic care may decrease fatigue in breast cancer patients undergoing chemotherapy. Some background The standard of care treatment option for breast cancer and...
Read More
In a nutshell This study looked survival rates of stage II rectal cancer patients who underwent different treatments. It compared radical surgery versus local excision with added-on chemoradiation. The article concluded that overall survival was not different between the treatments. Some background Radical surgery (RS – complete...
Read More
Video information: At the 2017 ASCO meeting in Chicago, Dr. George Simon and Dr. David Carbone talk about news and progress in small cell lung cancer. Dr. Simon goes into detail on some new promising approaches and current studies for small cell lung cancer treatment, adding "these are some of the newer, in my opinion, more exciting approaches...
Read More
In a nutshell This multicenter phase 3 clinical trial will test the effectiveness of nivolumab (Opdivo) after surgery and chemotherapy in stage 1b to 3a non-small cell lung cancer (NSCLC). The primary outcome will be measured by the length of time the patient survives without signs of the cancer and the overall survival rate for up to 10...
Read More
In a nutshell This study examined the safety and effectiveness of durvalumab (Imfinzi) in patients with stage III non-small cell lung cancer. This study concluded that durvalumab delayed time to disease progression. Some background Chemotherapy and radiation are the standard treatment options for stage III non-small cell lung cancer (NSCLC, cancer...
Read MoreIn a nutshell This study aimed to investigate if inotuzumab ozogamicin (Besponsa) is a more effective treatment than the standard therapy for relapsed acute lymphoblastic leukemia. This study concluded that inotuzumab ozogamicin is a more effective treatment than standard therapy for relapsed acute lymphoblastic leukemia. Some background...
Read More
In a nutshell This study aimed to investigate the adverse events of inotuzumab ozogamicin (Besponsa) for treatment of relapsed or refractory acute lymphoblastic leukaemia. This study concluded that inotuzumab ozogamicin leads to increased liver damage when compared to standard therapy. Some background Acute lymphoblastic leukaemia (ALL) occurs...
Read More
In a nutshell The aim of this study was to determine the effect of biomarkers to tailor therapy in advanced prostate cancer in patients receiving abiraterone (Zytiga) treatment. The authors concluded that alkaline phosphatase (ALP- protein elevated in the blood), lactate dehydrogenase (LDH – protein involved in tumor growth) and prostate...
Read More
In a nutshell This study examined the benefits of adding midostaurin (Rydapt) to standard chemotherapy in patients with acute myeloid leukemia (AML) and a genetic abnormality on the FLT3 gene. Authors reported improved treatment outcomes when AML patients with the FLT3 mutation were also treated with midostaurin. Some background AML is cancer of...
Read MoreIn a nutshell This study investigated ovarian function recovery (OFR) after chemotherapy-induced amenorrhea (absence of menstruation) in women aged 40-49 after 2 years of aromatase inhibitor (AI) therapy. The study concluded that a large number of women with chemotherapy-induced amenorrhea recover ovarian function during AI therapy. Some...
Read More
In a nutshell This study investigated the use of magnetic resonance (MR) imaging as a prognostic tool in primary breast cancer (BC) patients. The study concluded that MR imaging can identify features which can be used to help predict the risk of distant metastasis (cancer spread to other areas) in patients. Some background Between 20-30%...
Read More
